Loading...

Alphatec Holdings, Inc.

ATECNASDAQ
Healthcare
Medical - Devices
$15.84
$-0.30(-1.83%)

Alphatec Holdings, Inc. (ATEC) Financial Performance & Income Statement Overview

Analyze Alphatec Holdings, Inc. (ATEC) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.

Revenue Growth
26.81%
26.81%
Operating Income Growth
21.47%
21.47%
Net Income Growth
13.14%
13.14%
Operating Cash Flow Growth
43.11%
43.11%
Operating Margin
-16.40%
16.40%
Gross Margin
68.81%
68.81%
Net Profit Margin
-24.33%
24.33%
ROE
-251.82%
251.82%
ROIC
-17.59%
17.59%

Alphatec Holdings, Inc. (ATEC) Income Statement & Financial Overview

Analyze Alphatec Holdings, Inc.’s ATEC earnings with segmented quarterly and yearly financial statement figures.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$169.18M$176.79M$150.72M$145.57M
Cost of Revenue$53.18M$55.20M$47.99M$62.86M
Gross Profit$116.00M$121.59M$102.73M$82.72M
Gross Profit Ratio$0.69$0.69$0.68$0.57
R&D Expenses$16.58M$23.24M$20.36M$19.11M
SG&A Expenses$127.02M$114.54M$109.20M$96.69M
Operating Expenses$160.29M$145.41M$136.43M$115.80M
Total Costs & Expenses$213.47M$200.61M$181.40M$178.65M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$0.00$7.15M$6.57M$5.82M
Depreciation & Amortization-$161000.00$20.82M$21.92M$21.07M
EBITDA-$44.29M-$4.33M-$11.16M-$14.08M
EBITDA Ratio-$0.26-$0.02-$0.07-$0.10
Operating Income-$44.29M-$23.82M-$30.68M-$33.08M
Operating Income Ratio-$0.26-$0.13-$0.20-$0.23
Other Income/Expenses (Net)-$7.68M-$9.07M-$8.98M-$5.66M
Income Before Tax-$51.97M-$32.89M-$39.65M-$40.97M
Income Before Tax Ratio-$0.31-$0.19-$0.26-$0.28
Income Tax Expense-$64000.00$441000.00-$36000.00-$286000.00
Net Income-$51.91M-$33.33M-$39.62M-$40.68M
Net Income Ratio-$0.31-$0.19-$0.26-$0.28
EPS-$0.35-$0.23-$0.28-$0.29
Diluted EPS-$0.35-$0.23-$0.28-$0.29
Weighted Avg Shares Outstanding$146.73M$142.95M$143.49M$142.69M
Weighted Avg Shares Outstanding (Diluted)$146.73M$142.95M$143.49M$142.69M

The company's financials show resilient growth, with revenue advancing from $145.57M in Q2 2024 to $169.18M in Q1 2025. Gross profit remained healthy with margins at 69% in Q1 2025 compared to 57% in Q2 2024. Operating income hit -$44.29M last quarter, sustaining a consistent -26% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$44.29M. Net income dropped to -$51.91M, while earnings per share reached -$0.35. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;